Logo.jpg
Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 16:05 ET | Endonovo Therapeutics, Inc.
High-Growth Acquisition Approaches Completion, Expected To Augment Core Business And Drive Long-Term Shareholder Value Los Angeles, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc....
Logo.jpg
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021 08:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
Logo.jpg
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
June 15, 2020 08:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
Logo.jpg
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
April 16, 2020 08:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, April 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the addition of eight new hospitals Endonovo’s SofPulse®...
Logo.jpg
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
March 25, 2020 08:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse®...
Logo.jpg
Endonovo Therapeutics announces its collaboration with Major Universities for the Evaluation of SofPulse® for Orthopedic Surgeries
February 10, 2020 07:30 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced their SofPulse® device is being evaluated at major...
Logo.jpg
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers
January 30, 2020 07:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced sales of SofPulse® units to multiple Plastic Surgery...
Logo.jpg
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center
January 27, 2020 07:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced initial sales of SofPulse® units into a VA hospital in...
Logo.jpg
Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock
December 19, 2019 18:24 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today that its previously announced 1-for-1,000 reverse split of...
Logo.jpg
Endonovo Therapeutics Reports Third Quarter 2019 Results
November 19, 2019 16:35 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30,...